Table 2.
Relationship Between Clinical Characteristics and Gene Expression of PDZ-Binding Kinase in the HOVON-65/GMMG-HD4 Clinical Trial
N | PBK gene expression (Log2 value) |
P | |||||||
---|---|---|---|---|---|---|---|---|---|
Low | % | High | % | Ave. | SD | ||||
Total | 290 | 228 | 78.6 | 62 | 21.4 | 6.40 | 1.44 | ||
ISS | I | 114 | 98 | 86.0 | 16 | 14.0 | 6.10 | 1.36 | |
II | 71 | 52 | 73.2 | 19 | 26.8 | 6.61 | 1.34 | 0.047 (versus I) | |
III | 78 | 56 | 71.8 | 22 | 28.2 | 6.70 | 1.53 | 0.011 (versus I) | |
NA | 27 | 22 | 81.5 | 5 | 18.5 | 6.23 | 1.56 |
PBK expression low, log2 <7.5; PBK expression high, log2 >7.5. The statistical analysis was performed using one-way ANOVA with pairwise comparison (Turkey).
ANOVA, analysis of variance; ISS, International Staging System; NA, not analyzed; PBK, PDZ-binding kinase; SD, standard deviation.